Covid-19 roundup: Pfiz­er CEO Bourla to write book about vac­cine arms race; Chi­nese mR­NA shot set for PhI­II tri­al in ...

4 years ago
Coronavirus

Bio­gen push­es in a fresh stack of chips and starts prep­ping a glob­al R&D game plan af­ter watch­ing the cards turn on ...

4 years ago
Deals
R&D

Luisa Salter-Cid joins long­time Bris­tol My­ers col­lab­o­ra­tor Paul Bion­di at Flag­ship's new drug brew­ery

4 years ago
People

With back­ing from Bay­er, a Lon­don firm will pitch its 'hos­pi­tals at home' con­cept for de­cen­tral­ized tri­als

4 years ago
Financing
Startups

Per­cep­tive Ad­vi­sors, Xon­toge­ny bring the band back and then some with a $515M sec­ond fund sniff­ing out lead com­pounds

4 years ago
Financing

The grow­ing liq­uid biop­sy field sees a uni­corn en­trant as Caris pulls in $830M megaround

4 years ago
Financing

A clos­er look at the FDA’s more than 700 pan­dem­ic-re­lat­ed record re­quests to re­place on­site in­spec­tions

4 years ago
FDA+
Manufacturing

Alex­ion co-founder Stephen Squin­to is back in the game as CEO, this time for a small gene ther­a­py play­er

4 years ago
People
Financing

George Golumbes­ki signs on at a Eu­ro­pean spe­cial­ist VC firm with $265M to bet on ge­net­ic dis­eases

4 years ago
People
Financing

Opin­ion: Ado­les­cents can wait. The US needs to start do­nat­ing Covid-19 vac­cines to needy coun­tries now.

5 years ago
FDA+
Opinion

Can a rare im­mune cell of­fer the key to slow­ing down senes­cence? A Bay Area start­up looks to find out

5 years ago
Startups

Prothena col­lects $60M Parkin­son's mile­stone from Roche; As­traZeneca's Pas­cal So­ri­ot faces proxy push­back on pay ...

5 years ago
News Briefing

The in­cu­ba­tor that hatched a Jen­nifer Doud­na CRISPR start­up blue­prints new 'des­ti­na­tion for life sci­ence ...

5 years ago
Startups

The fight against drug-re­sis­tant bac­te­ria march­es for­ward as Adap­tive Phage earns $40M+ Se­ries B

5 years ago
Financing

Is re­mote work here to stay for bio­phar­ma? Ear­ly in­di­ca­tions point to yes

5 years ago
Pharma

Bio­gen en­lists un­der-the-radar AAV en­gi­neers as it pumps gene ther­a­pies in­to the pipeline

5 years ago
Deals

An Ab­b­Vie clin­i­cal vet head­ing ear­ly on­col­o­gy jumps ship to build his own team at NK cell-fo­cused biotech

5 years ago
People
Cell/Gene Tx

Covid-19 roundup: FDA au­tho­rizes Pfiz­er/BioN­Tech vac­cine for 12- to 15-year-olds; No­vavax shares sink as com­pa­ny ...

5 years ago
Coronavirus

Lil­ly en­lists a long-in­cu­bat­ing RNA up­start in new $1.25B part­ner­ship

5 years ago
Deals

Months af­ter emerg­ing from stealth, Nu­va­lent fol­lows up with $135M Se­ries B — backed by some ac­tive play­ers on the ...

5 years ago
Financing

Gink­go Bioworks re­sizes the de­f­i­n­i­tion of go­ing big in biotech, rais­ing $2.5B in a record SPAC deal that weighs in ...

5 years ago
Financing

RWE up­start maps a new glob­al plan as in­vestors pour in the lat­est mega-round

5 years ago
Financing
FDA+

No­bel lau­re­ate David Bal­ti­more throws his weight be­hind I/O start­up look­ing to craft off-the-shelf CAR ther­a­pies

5 years ago
Financing
Cell/Gene Tx

Ex-Pur­due Phar­ma chief Mark Tim­ney, named in dozens of opi­oid law­suits, nabs an­oth­er biotech CEO gig

5 years ago
People
First page Previous page 694695696697698699700 Next page Last page
A service from the Financial Times